醒后缺血性卒中替奈普酶试验(TWIST)的统计分析计划
TWIST是一项随机对照试验,纳入醒后急性缺血性卒中患者,在觉醒后4.5小时内依据非增强CT可治疗者,比较静脉替奈普酶0.25 mg/kg联合标准治疗与单纯标准治疗(不溶栓)。本文在揭盲前发布详细统计分析计划,遵循CONSORT声明,旨在减少报告偏倚并明确预设分析。
要点
- TWIST纳入醒后急性缺血性卒中且觉醒后4.5小时内可治疗的患者。
- 干预为静脉替奈普酶0.25 mg/kg联合标准治疗,对照为单纯标准治疗(不溶栓)。
- 统计分析计划在揭盲前发布,遵循CONSORT声明,明确预设分析。
核心结论
- 发布统计分析计划有助于减少潜在试验报告偏倚并清晰列出预设分析。
研究设计与样本
- TWIST为随机对照试验,比较静脉替奈普酶0.25 mg/kg联合标准治疗与单纯标准治疗(不溶栓)。
- 纳入醒后急性缺血性卒中患者,依据非增强CT结果在觉醒后4.5小时内可治疗。
- 统计分析计划与CONSORT声明一致,提供清晰开放的报告。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with wake-up ischemic stroke are frequently excluded from thrombolytic treatment due to unknown symptom onset time and limited availability of advanced imaging modalities. The Tenecteplase in Wake-up Ischaemic Stroke Trial (TWIST) is a randomized controlled trial of intravenous tenecteplase 0.25 mg/kg and standard care versus standard care alone (no thrombolysis) in patients who wake up with acute ischemic stroke and can be treated within 4.5 h of wakening based on non-contrast CT findings. OBJECTIVE: To publish the detailed statistical analysis plan for TWIST prior to unblinding. METHODS: The TWIST statistical analysis plan is consistent with the Consolidating Standard of Reporting Trials (CONSORT) statement and provides clear and open reporting. DISCUSSION: Publication of the statistical analysis plan serves to reduce potential trial reporting bias and clearly outlines the pre-specified analyses. TRIAL REGISTRATION: ClinicalTrials.gov NCT03181360 . EudraCT Number 2014-000096-80 . WHO ICRTP registry number ISRCTN10601890 .
引用
- Eltoft A, Wilsgaard T, Roaldsen MB, et al. Statistical analysis plan for the randomized controlled trial Tenecteplase in Wake-up Ischaemic Stroke Trial (TWIST). Trials. 2022. PMID: 35590386. doi:10.1186/s13063-022-06301-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。